ArticleIndustrial psychiatry journal
Arecanut dependence and awareness of adverse effects of arecanut use in patients with psychiatric illnesses.
Article in Industrial psychiatry journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tobacco and arecanut use are commonly seen in patients with psychiatric illnesses. Aim: Assess dependence on arecanut, and the level of awareness of the adverse effects of arecanut use in psychiatric patients. Materials and Methods: A hospital-based cross-sectional study was performed. The sample comprised 100 newly diagnosed and old follow-up patients of psychiatric illness, aged above 18 years. Patients were recruited to the study by convenience sampling. Socio-demographic pro forma, Betel Quid Dependence Scale (BQDS), and self-designed awareness pro forma were used for data collection. Statistical analysis was performed using SPSS Version 22 for Windows. Results: Arecanut use was seen in 42% of the total sample. The association between total duration of arecanut use was greater in non-psychotic patients (85%; Conclusions: Among psychiatric patients' substance use, like arecanut, is much higher compared to the general population. Part of the reason for the higher use is a lack of awareness about the adverse effects of arecanut use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.